En­do Phar­ma­ceu­ti­cals chops 560 jobs to re­fo­cus on cel­lulite drug launch

Less than a month af­ter ink­ing a $658 mil­lion deal to buy out BioSpecifics Tech­nolo­gies, En­do Phar­ma­ceu­ti­cals is shut­ter­ing mul­ti­ple man­u­fac­tur­ing sites and cut­ting 560 jobs to re­fo­cus on a drug launch in the spring.

The re­struc­tur­ing will oc­cur in phas­es over the next few years, En­do $ENDP said Thurs­day. The Dublin-based biotech will grad­u­al­ly ex­it man­u­fac­tur­ing sites in Irvine, CA and Chest­nut Ridge, NY, and API man­u­fac­tur­ing and bioe­quiv­a­lence study sites in In­dia through the sec­ond half of 2022. Plus, it plans on trim­ming ad­min­is­tra­tive costs by out­sourc­ing “cer­tain trans­ac­tion pro­cess­ing ac­tiv­i­ties.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER